Trial · NCT00408200
A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
NCT00408200, Not applicable, Completed, University of Pennsylvania; results first posted 2013-03-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation. Trials, record NCT00408200. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00408200
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
- NCT number
- NCT00408200
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 110 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Atrial Fibrillation
- Interventions
- propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation
- First posted
- 2006-12-06
- Last updated
- 2013-03-07
- Results first posted
- 2013-03-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | 6 weeks | |
| Secondary | Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | 6 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | 6 weeks | Assuming an incidence of the composite primary end point of 40% in the control group and a 50% reduction in the composite primary end point in the drug treatment group, we calculated that 160 patients would have to be included in the study in order to obtain a power of 80% and with a 2-tailed error of 0.05. | participants | NUMBER |
| SECONDARY | Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | 6 weeks | Assuming an incidence of the composite primary end point of 40% in the control group and a 50% reduction in the composite primary end point in the drug treatment group, we calculated that 160 patients would have to be included in the study in order to obtain a power of 80% and with a 2-tailed error of 0.05. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | AAD:NO | 24 | participants | ||
Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | AAD:YES | 10 | participants | ||
| Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | AAD:NO | 39 | participants | ||
| Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | AAD:YES | 35 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AAD:NO | 57 | |
| Overall Study | STARTED | AAD:YES | 53 | |
| Overall Study | COMPLETED | AAD:NO | 57 | |
| Overall Study | COMPLETED | AAD:YES | 53 | |
| Overall Study | NOT COMPLETED | AAD:NO | 0 | |
| Overall Study | NOT COMPLETED | AAD:YES | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AAD:NO | ||
| Total, all-cause mortality | AAD:YES | ||
| Total, other adverse events | AAD:NO | 0 | 57 |
| Total, other adverse events | AAD:YES | 0 | 53 |
| Total, serious adverse events | AAD:NO | 0 | 57 |
| Total, serious adverse events | AAD:YES | 0 | 53 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| AAD:NO vs AAD:YES: Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | Trial comparisons |
AAD:NO vs AAD:YES: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | Trial comparisons |
| AAD:NO vs AAD:YES: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00408200
GET https://conductscience.org/api/trials/v1/NCT00408200/registered